Median overall survival with olaparib plus abiraterone reached 68 months in mid-stage tria ...

Relapse rates over 3 years did not differ with glucocorticoid withdrawal vs maintenance among patients with stable SjD-ILD.

Capivasertib+abiraterone was associated with more symptomatic AEs but did not impact HRQoL in patients with PTEN-deficient ...

Anifrolumab yielded positive outcomes, including remission in 26% of patients, at 6 months across a real-word, multicenter cohort of patients with systemic lupus erythematosus, according to data ...

Initiating mepolizumab within 3 months of EGPA diagnosis is associated with a higher remission rate, earlier glucocorticoid withdrawal, and less damage accrual.

A new study published in the Journal of the American Medical Association showed that for juvenile dermatomyositis (JDM), a combination of intermittent intravenous methylprednisolone pulse ...

Objective Systemic lupus erythematosus (SLE) is associated with increased susceptibility to infections, including herpes ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...

Initiating add-on therapy within 2 years of a myasthenia gravis (MG) diagnosis was associated with a stronger and more consistent clinical response, according to a new study published in the Journal ...

More than 80% of patients with newly diagnosed rheumatoid arthritis, who were using bridging therapy, successfully tapered ...

The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing ...

Feb 26 (Reuters) - Eli Lilly's experimental weight-loss pill, orforglipron, caused more side effects and treatment ...